GPRC5D Protein-VLP, Human (HEK293, C-His)

GPRC5D Protein-VLP, Human (HEK293, C-His) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P701236. Tags can only be detected under denaturing conditions.

G protein-coupled receptor class C 5 member D (GPRC5D) is a G protein-coupled orphan receptor that shares homology with mammalian G protein-coupled receptors (GPCRs) superfamily C family group 5 member (related to metabotropic glutamate receptor-like) and belongs to the RAIG1 family along with two highly homologous orphan G protein-coupled receptors (oGPCRs), GPRC5B and GPRC5C (RAIG1 was originally isolated as an orphan GPCR by differential display, and its expression can be induced by all-trans retinoic acid (ATRA) in human head and neck squamous cell carcinoma (HNSCC)). As a member of the G protein-coupled receptor that only exists in eukaryotes (including yeast and flagella), GPRC5D is mainly expressed on malignant plasma cells, but limitedly expressed in normal tissues. It is a potential therapeutic target for relapsed/refractory multiple myeloma (R/R MM). Its targeted CAR-T, CAR-NK cell therapy and bispecific T cell engagers have significant anti-tumor activity, and it is also a target for CAR-T cell immunotherapy of multiple myeloma. In addition, G protein-coupled receptors can be bound and activated by a variety of ligands (ranging in size from small molecules to large proteins), such as photosensitive compounds, odors, and hormones, and are associated with a variety of diseases. Its signal transduction pathways include the cAMP signaling pathway and the phosphatidylinositol signaling pathway.

Human

HEK293

C-10*His

Q9NZD1-1 (M1-V345)

55507  [NCBI]

Full Length of Isoform-1

MYKDCIESTGDYFLLCDAEGPWGIILESLAILGIVVTILLLLAFLFLMRKIQDCSQWNVLPTQLLFLLSVLGLFGLAFAFIIELNQQTAPVRYFLFGVLFALCFSCLLAHASNLVKLVRGCVSFSWTTILCIAIGCSLLQIIIATEYVTLIMTRGMMFVNMTPCQLNVDFVVLLVYVLFLMALTFFVSKATFCGPCENWKQHGRLIFITVLFSIIIWVVWISMLLRGNPQFQRQPQWDDPVVCIALVTNAWVFLLLYIVPELCILYRSCRQECPLQGNACPVTAYQHSFQVENQELSRARDSDGAEEDVALTSYGTPIQPQTVDPTQECFIPQAKLSPQQDAGGV

Purity analysis by SDS-PAGE is not available for VLP proteins.

<1 EU/μg, determined by LAL method.

• [1]. Jieyun Xia, et al. Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting. J Hematol Oncol. 2023 Jun 5;16(1):60.  [Content Brief]

  [2]. Shinichi Inoue, et al. The RAIG family member, GPRC5D, is associated with hard-keratinized structures. J Invest Dermatol. 2004 Mar;122(3):565-73.  [Content Brief]